Renaissance Technologies LLC boosted its position in CryoLife, Inc. (NYSE:CRY) by 4.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 547,900 shares of the medical equipment provider’s stock after buying an additional 20,900 shares during the period. Renaissance Technologies LLC owned 1.69% of CryoLife worth $9,123,000 as of its most recent filing with the SEC.
Several other large investors have also recently bought and sold shares of the company. UBS Group AG increased its position in shares of CryoLife by 18.3% in the first quarter. UBS Group AG now owns 47,302 shares of the medical equipment provider’s stock worth $787,000 after buying an additional 7,332 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in CryoLife by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,849,248 shares of the medical equipment provider’s stock worth $30,790,000 after buying an additional 100,125 shares during the period. Axiom International Investors LLC DE raised its stake in CryoLife by 31.5% in the first quarter. Axiom International Investors LLC DE now owns 158,945 shares of the medical equipment provider’s stock worth $2,646,000 after buying an additional 38,083 shares during the period. Geode Capital Management LLC raised its stake in shares of CryoLife by 2.9% in the first quarter. Geode Capital Management LLC now owns 207,318 shares of the medical equipment provider’s stock valued at $3,451,000 after buying an additional 5,931 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of CryoLife by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,556,106 shares of the medical equipment provider’s stock valued at $25,909,000 after buying an additional 43,212 shares during the last quarter. 68.15% of the stock is owned by institutional investors.
CryoLife, Inc. (CRY) opened at 18.65 on Wednesday. The stock’s 50 day moving average price is $19.35 and its 200 day moving average price is $17.95. The firm has a market capitalization of $623.77 million, a PE ratio of 56.52 and a beta of 0.98. CryoLife, Inc. has a 52-week low of $13.88 and a 52-week high of $20.30.
CryoLife (NYSE:CRY) last issued its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.02. The company had revenue of $47.80 million during the quarter, compared to the consensus estimate of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period last year, the business posted $0.13 EPS. On average, analysts predict that CryoLife, Inc. will post $0.43 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Renaissance Technologies LLC Has $9.12 Million Position in CryoLife, Inc. (NYSE:CRY)” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2017/08/02/renaissance-technologies-llc-increases-stake-in-cryolife-inc-nysecry-updated.html.
Several analysts recently commented on the company. BidaskClub lowered CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday. Northland Securities restated a “buy” rating and set a $23.50 target price on shares of CryoLife in a research report on Friday, April 28th. Finally, Zacks Investment Research raised CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Thursday, June 8th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $22.00.
In other news, VP Amy Horton sold 9,577 shares of the firm’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total value of $191,540.00. Following the completion of the sale, the vice president now directly owns 112,282 shares in the company, valued at approximately $2,245,640. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.00% of the company’s stock.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
